✦ LIBER ✦

Phase I safety, pharmacokinetic and pharmacodynamic study of recombinant human anti-VEGF antibody HuMV833 in patients with advanced cancer

Book ID: 117659597
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 140 KB
Volume: 38
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(02)80905-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I investigation of recombinant ant

Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer

✍ Gordon C. Jayson; Clive Mulatero; Malcolm Ranson; Jamal Zweit; Alan Jackson; Lyn 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 215 KB

Phase I Safety and Pharmacokinetic Study

Phase I Safety and Pharmacokinetic Study of Bavituximab, a Chimeric Phosphatidylserine-Targeting Monoclonal Antibody, in Patients with Advanced Solid Tumors

✍ Gerber, D. E.; Stopeck, A. T.; Wong, L.; Rosen, L. S.; Thorpe, P. E.; Shan, J. S 📂 Article 📅 2011 🏛 American Association for Cancer Research 🌐 English ⚖ 346 KB

Phase I and pharmacokinetic study of d-l

Phase I and pharmacokinetic study of d-limonene in patients with advanced cancer

✍ David M. Vigushin; Grace K. Poon; Alan Boddy; Jacqueline English; Gavin W. Halbe 📂 Article 📅 1998 🏛 Springer 🌐 English ⚖ 307 KB

Phase I and pharmacokinetic study of vat

Phase I and pharmacokinetic study of vatalanib plus capecitabine in patients with advanced cancer

✍ Richard L. Schilsky; David Geary; Linda Skoog; Apurva A. Desai; Joyce Valickas; 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 163 KB

Phase I safety, pharmacokinetic, and pha

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors

✍ Markman, B.; Tabernero, J.; Krop, I.; Shapiro, G. I.; Siu, L.; Chen, L. C.; Mita 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 362 KB

Phase I Study of the Anti-MUC-l Antibody

Phase I Study of the Anti-MUC-l Antibody, huHMFG1 (AS1402), in Patients with Advanced Breast Cancer

✍ Nigel Courtenay-Luck; Mark Pegram 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 51 KB